drugset / Trial / NCT03032614
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.
Timeline
- Start
- 2017-09-30
- Primary completion
- 2019-03-31
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Eribulin | Small molecule | 1.1 mg/m2 | Intravenous |
| Subject | Veliparib | Small molecule | 240 mg | — |